Semaglutide is an effective, non-surgical weight loss option that helps patients struggling with: In clinical trials, patients taking semaglutide lost an average of 15% of their body weight compared to those on a placebo
Translating animal dosing to human equivalents introduces risk without clinical guidance
GLP-1 medications like Ozempic, Wegovy, and Mounjaro are powerful tools for weight loss
However, they can also occur sporadically without any known genetic predisposition (Evans et al., 2021)
Short-acting agents primarily work by slowing gastric emptying to reduce postprandial blood glucose levels, while long-acting GLP-1 RAs are more effective at lowering fasting blood glucose levels, mainly by promoting insulin secretion and inhibiting glucagon release
In doing this, it allows you to feel less hungry after smaller meals, making it significantly easier to eat less throughout the day